Bank of New York Mellon Corp Sells 5,282 Shares of Theravance Biopharma, Inc. (NASDAQ:TBPH)

Bank of New York Mellon Corp trimmed its stake in Theravance Biopharma, Inc. (NASDAQ:TBPH) by 4.4% during the fourth quarter, HoldingsChannel.com reports. The fund owned 115,779 shares of the biopharmaceutical company’s stock after selling 5,282 shares during the quarter. Bank of New York Mellon Corp’s holdings in Theravance Biopharma were worth $1,089,000 at the end of the most recent reporting period.

Several other hedge funds have also recently bought and sold shares of the stock. Jane Street Group LLC boosted its stake in shares of Theravance Biopharma by 1.1% in the 3rd quarter. Jane Street Group LLC now owns 144,575 shares of the biopharmaceutical company’s stock valued at $1,165,000 after purchasing an additional 1,640 shares in the last quarter. SG Americas Securities LLC boosted its position in Theravance Biopharma by 21.1% in the fourth quarter. SG Americas Securities LLC now owns 19,202 shares of the biopharmaceutical company’s stock valued at $181,000 after buying an additional 3,349 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank grew its stake in Theravance Biopharma by 29.1% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 16,978 shares of the biopharmaceutical company’s stock worth $137,000 after buying an additional 3,827 shares during the last quarter. XTX Topco Ltd increased its holdings in shares of Theravance Biopharma by 34.5% during the third quarter. XTX Topco Ltd now owns 20,439 shares of the biopharmaceutical company’s stock worth $165,000 after buying an additional 5,243 shares in the last quarter. Finally, Martingale Asset Management L P raised its stake in shares of Theravance Biopharma by 14.4% in the third quarter. Martingale Asset Management L P now owns 54,450 shares of the biopharmaceutical company’s stock valued at $439,000 after acquiring an additional 6,870 shares during the last quarter. 99.10% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Theravance Biopharma

In other news, SVP Rhonda Farnum sold 4,000 shares of Theravance Biopharma stock in a transaction that occurred on Tuesday, January 21st. The shares were sold at an average price of $9.00, for a total transaction of $36,000.00. Following the completion of the sale, the senior vice president now owns 309,565 shares in the company, valued at $2,786,085. The trade was a 1.28 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 6.90% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright restated a “buy” rating and set a $15.00 price target on shares of Theravance Biopharma in a research report on Tuesday, February 25th. Four analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. According to MarketBeat.com, Theravance Biopharma presently has an average rating of “Hold” and an average target price of $13.75.

Theravance Biopharma Stock Performance

TBPH opened at $9.39 on Tuesday. Theravance Biopharma, Inc. has a 1-year low of $7.44 and a 1-year high of $10.90. The stock has a market capitalization of $464.53 million, a PE ratio of -9.30 and a beta of 0.15. The firm has a 50-day moving average price of $9.34 and a two-hundred day moving average price of $9.07.

Theravance Biopharma (NASDAQ:TBPH) last released its quarterly earnings results on Wednesday, February 26th. The biopharmaceutical company reported ($0.31) EPS for the quarter, missing the consensus estimate of ($0.05) by ($0.26). Theravance Biopharma had a negative net margin of 78.18% and a negative return on equity of 24.79%. The company had revenue of $18.75 million for the quarter, compared to the consensus estimate of $29.90 million. On average, research analysts predict that Theravance Biopharma, Inc. will post -1.09 EPS for the current year.

Theravance Biopharma Company Profile

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.